BioSpace News Archive

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of David Ailinger as Vice President, Business Development, reporting directly to Patrick J. McEnany, Catalyst’s Chairman and CEO.

Inato, a platform that helps biopharmaceutical companies increase the pool of available patients engaged in clinical trials, announced it has raised a $14 million Series A round of venture capital financing.

Viralgen, a world-leading GMP manufacturer of AAV therapeutics, makes significant contribution in manufacturing capacity to serve children in need

CNS Pharmaceuticals, Inc. announced it has completed the final GMP manufacturing run of its lead candidate Berubicin, which it acquired from Reata Pharmaceuticals, Inc., and that the GMP material has met all specifications.

Heska Corporation, a provider of advanced veterinary diagnostic and specialty products, plans to report its fourth quarter and full year 2019 financial performance in a press release on Tuesday, February 25, 2020 before the market opens, and to host an earnings call to discuss the results following the release at 9 a.m. MT / 11 a.m. ET..

VirTrial announced its international expansion with a newly appointed International Director of Business Development, a network of virtual trial capable research sites across 31 countries, policies supporting GDPR compliance, and product enhancements that support language translation into any left to right reading language.

Horizon Therapeutics plc announced that its fourth-quarter and full-year 2019 financial results will be released on Wednesday, Feb. 26, 2020.

The SPIE-Glebov UCF graduate student scholarship is part of a $2.5 million SPIE education funding initiative for optics and photonics

OncoSec Medical Incorporated, a company developing late-stage intratumoral cancer immunotherapies, announced the publication of data showing that TAVO™ treatment, administered through OncoSec’s electroporation gene delivery system, resulted in regression of injected and non-injected Merkel cell carcinoma tumors.

ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced a one-for-ten reverse stock split of its shares of common stock.